Company News for GNTA
Genta Incorporated To Present At UBS Warburg Life Sciences Conference
BERKELEY HEIGHTS, N.J., Oct 1, 2002 /PRNewswire-FirstCall via COMTEX/ -- Genta Incorporated (Nasdaq: GNTA) announced today that Dr. Raymond P. Warrell, Jr., Chairman and Chief Executive Officer, will present an overview of the Company's strategic plans and recent highlights at the UBS Warburg Life Sciences Conference in New York City. Dr. Warrell's presentation will take place on Monday, October 7, 2002, at 4:30 pm EDT.
A live audio webcast will be available during the presentation via the investor relations section of the Company's website at: genta.com
The presentation will be archived for 30 days.
Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on anticancer therapy. The Company's research platform is anchored by oligonucleotide chemistry, particularly applications of antisense and decoy aptamer technology. Genasense(TM), the Company's lead compound, is being developed in collaboration with Aventis and is currently undergoing late-stage, Phase 3 clinical testing in several clinical indications. Genta's pipeline also comprises a portfolio of small molecules, including gallium-containing compounds and Androgenics compounds for prostate cancer. For more information about Genta, please visit our website at: genta.com.
The statements contained in this press release and the presentation to follow that are not historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the expectations, beliefs, intentions or strategies regarding the future. Without limiting the foregoing, the words "anticipates," "believes," "expects," "intends," "may" and "plans" and similar expressions are intended to identify forward-looking statements. The Company intends that all forward-looking statements be subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect the Company's views as of the date they are made with respect to future events, but are subject to many risks and uncertainties, which could cause the actual results of the Company to differ materially from any future results expressed or implied by such forward-looking statements. For example, the results obtained in pre-clinical or clinical studies may not be indicative of results that will be obtained in future clinical trials, and delays in the initiation or completion of clinical trials may occur as a result of many factors. Further examples of such risks and uncertainties also include, but are not limited to: the obtaining of sufficient financing to maintain the Company's planned operations; timely development, receipt of necessary regulatory approvals, and acceptance of new products; the successful application of the Company's technology to produce new products; the obtaining of proprietary protection for any such technology and products; the impact of competitive products and pricing and reimbursement policies; and changing market conditions. The Company does not undertake to update forward-looking statements. Although the Company believes that the forward-looking statements contained herein are reasonable, it can give no assurances that the Company's expectations are correct. All forward looking statements are expressly qualified in their entirety by this cautionary statement and other factors detailed in the Company's reports filed with the Securities and Exchange Commission.
MAKE YOUR OPINION COUNT - Click Here tbutton.prnewswire.com
SOURCE Genta Incorporated
CONTACT: Tara Spiess, Director, Corporate Communications, Genta Incorporated, +1-908-286-3980
URL: genta.com prnewswire.com
Copyright (C) 2002 PR Newswire. All rights reserved.
-0-
KEYWORD: New Jersey INDUSTRY KEYWORD: BIO HEA MTC SUBJECT CODE: TDS CCA |
